18F-FDG PET Imaging of Myocardial Viability in an Experienced Center with Access to 18F-FDG and Integration with Clinical Management Teams: The Ottawa-FIVE Substudy of the PARR 2 Trial

被引:109
|
作者
Abraham, Arun [1 ,2 ]
Nichol, Graham [3 ]
Williams, Kathryn A. [1 ,2 ]
Guo, Ann [1 ,2 ]
deKemp, Robert A. [1 ,2 ]
Garrard, Linda [1 ,2 ]
Davies, Ross A. [1 ,2 ]
Duchesne, Lloyd [1 ,2 ]
Haddad, Haissam [1 ,2 ]
Chow, Benjamin [1 ,2 ]
DaSilva, Jean [1 ,2 ]
Beanlands, Rob S. B. [1 ,2 ]
机构
[1] Univ Ottawa, Inst Heart, Natl Cardiac PET Ctr, Ottawa, ON K1Y 4W7, Canada
[2] Univ Ottawa, Inst Heart, Div Cardiol, Cardiovasc Res Methods Ctr, Ottawa, ON K1Y 4W7, Canada
[3] Univ Washington, Harborview Ctr Prehosp Emergency Care, Seattle, WA 98195 USA
关键词
cardiology (clinical); PET; fluorodeoxyglucose; LV dysfunction; viability; LEFT-VENTRICULAR DYSFUNCTION; POSITRON-EMISSION-TOMOGRAPHY; CORONARY-ARTERY-DISEASE; RANDOMIZED-TRIALS; REVASCULARIZATION; PROGNOSIS; MORTALITY; SUBGROUP; INFARCTION; SURVIVAL;
D O I
10.2967/jnumed.109.065938
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
F-18-FDG PET may assist decision making in ischemic cardiomyopathy. The PET and Recovery Following Revascularization (PARR 2) trial demonstrated a trend toward beneficial outcomes with PET-assisted management. The substudy of PARR 2 that we call Ottawa-FIVE, described here, was a post hoc analysis to determine the benefit of PET in a center with experience, ready access to F-18-FDG, and integration with clinical teams. Methods: Included were patients with left ventricular dysfunction and suspected coronary artery disease being considered for revascularization. The patients had been randomized in PARR 2 to PET-assisted management (group 1) or standard care (group 2) and had been enrolled in Ottawa after August 1, 2002 (the date that on-site F-18-FDG was initiated) (n = 111). The primary outcome was the composite endpoint of cardiac death, myocardial infarction, or cardiac rehospitalization within 1 y. Data were compared with the rest of PARR 2 (PET-assisted management [group 3] or standard care [group 4]). Results: In the Ottawa-FIVE subgroup of PARR 2, the cumulative proportion of patients experiencing the composite event was 19% (group 1), versus 41% (group 2). Multivariable Cox proportional hazards regression showed a benefit for the PET-assisted strategy (hazard ratio, 0.34; 95% confidence interval, 0.16-0.72; P = 0.005). Compared with other patients in PARR 2, Ottawa-FIVE patients had a lower ejection fraction (25% +/- 7% vs. 27% +/- 8%, P = 0.04), were more often female (24% vs. 13%, P = 0.006), tended to be older (64 +/- 10 y vs. 62 +/- 10 y, P = 0.07), and had less previous coronary artery bypass grafting (13% vs. 21%, P = 0.07). For patients in the rest of PARR 2, there was no significant difference in events between groups 3 and 4. The observed effect of F-18-FDG PET-assisted management in the 4 groups in the context of adjusted survival curves demonstrated a significant interaction (P = 0.016). Comparisons of the 2 arms in Ottawa-FIVE to the 2 arms in the rest of PARR 2 demonstrated a trend toward significance (standard care, P = 0.145; PET-assisted management, P = 0.057). Conclusion: In this post hoc group analysis, a significant reduction in cardiac events was observed in patients with F-18-FDG PET-assisted management, compared with patients who received standard care. The results suggest that outcome may be benefited using F-18-FDG PET in an experienced center with ready access to F-18-FDG and integration with imaging, heart failure, and revascularization teams.
引用
收藏
页码:567 / 574
页数:8
相关论文
共 50 条
  • [21] 18F-FDG PET/CT in the clinical management of patients with lymphoma
    Tamayo, P.
    Martin, A.
    Diaz, L.
    Cabrero, M.
    Garcia, R.
    Garcia-Talavera, P.
    Caballero, D.
    REVISTA ESPANOLA DE MEDICINA NUCLEAR E IMAGEN MOLECULAR, 2017, 36 (05): : 312 - 321
  • [22] 18F-FDG PET/CT for the clinical management of patients with sarcoidosis
    Gajate, A. Samanes
    Incerti, E.
    Cremona, G.
    Dal Farra, S.
    Mapelli, P.
    Gianolli, L.
    Picchio, M.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2014, 41 : S596 - S596
  • [23] Physiologic uptake of 18F-FDG in transposed ovaries may mimic metastasis on 18F-FDG PET/CT imaging
    Davidson, Tima
    Komisar, Orna
    Korach, Jacob
    Felder, Shira
    Apter, Sara
    Ben-Haim, Simona
    Perri, Tamar
    NUCLEAR MEDICINE COMMUNICATIONS, 2018, 39 (02) : 171 - 178
  • [24] 18F-FDG PET/CT for the Assessment of Myocardial Sarcoidosis
    Skali, Hicham
    Schulman, Allison R.
    Dorbala, Sharmila
    CURRENT CARDIOLOGY REPORTS, 2013, 15 (04)
  • [25] Reverse mismatch pattern on 18F-FDG myocardial PET
    Vignati, A.
    Songini, C.
    Cammelli, F.
    Carletto, M.
    Siczek, K.
    Maffioli, L.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2012, 39 : S427 - S428
  • [26] Clinical Cerenkov Luminescence Imaging of 18F-FDG
    Thorek, Daniel L. J.
    Riedl, Christopher C.
    Grimm, Jan
    JOURNAL OF NUCLEAR MEDICINE, 2014, 55 (01) : 95 - 98
  • [27] 18F-FDG PET/CT for the Assessment of Myocardial Sarcoidosis
    Hicham Skali
    Allison R. Schulman
    Sharmila Dorbala
    Current Cardiology Reports, 2013, 15
  • [28] 18F-FDG PET imaging of muscle activity in runners
    Tashiro, M
    Fujimoto, T
    Itoh, M
    Kubota, K
    Fujiwara, T
    Miyake, M
    Watanuki, S
    Horikawa, E
    Sasaki, H
    Ido, T
    JOURNAL OF NUCLEAR MEDICINE, 1999, 40 (01) : 70 - 76
  • [29] 18F-FDG PET/CT imaging of trichoblastoma of the knee
    Nguyen, B. D.
    DiCaudo, D. J.
    REVISTA ESPANOLA DE MEDICINA NUCLEAR E IMAGEN MOLECULAR, 2019, 38 (03): : 192 - 194
  • [30] 18F-FDG PET imaging of progressive massive fibrosis
    Soo Yoon Chung
    Jae Hoon Lee
    Tae Hoon Kim
    Sang Jin Kim
    Hyung Joong Kim
    Young Hoon Ryu
    Annals of Nuclear Medicine, 2010, 24 : 21 - 27